SKY-0515

Name: SKY-0515 in Huntington's disease: Generic, brand name and therapeutic class of product
Published: 2026-09-16T18:00:43-04:00

Huntington's disease

Manufacturer: Skyhawk Therapeutics
Regulatory submission: TGA provisional approval application submitted March 2026
Launch: Anticipated as early as 2027, market not specified
Last updated: October 1, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 3 sources

Manufacturer: Skyhawk Therapeutics

“Skyhawk Therapeutics, Inc.” (opens the source at this quote in a new tab)

Product names

“Study Drug Name (INN): SKY-0515” (opens the source at this quote in a new tab)

Nonproprietary name and brand name

No evidence found.

Therapeutic class

“SKY-0515 is an orally administered investigational small molecule RNA splicing modifier developed using the company's proprietary SKYSTAR platform. SKY-0515 is designed to reduce both mHTT and PMS1 proteins.” (opens the source at this quote in a new tab)